Skip to content
Search

Latest Stories

NHS drug costs in England rose by almost 8%

The total cost to NHS commissioners for medicines, appliances and medicines devices in 2022-23 was £19.2 billion

The NHS Business Services Authority (NHSBSA) has published the latest figures for prescribing costs in primary and secondary care in England.


The total cost to NHS commissioners for the issue of medicines, appliances, and medical devices in 2022-23 is estimated to be £19.2 billion excluding central rebates, an increase of 7.99% from £17.8 billion in 2021-22.

This is the second time in two years that NHS drug costs in England have increased by this size.

Data published by the NHSBSA in November 2022 showed that the total prescribing costs rose by 8 per cent in 2021/2022 (£17.8bn) compared with 2020/2021 (£16.4bn).

After a deduction of £674m for central rebates, the total cost is estimated to be £18.5 billion.

The central rebate figure includes rebates from arrangements NHSEI have agreed with pharmaceutical companies following successful negotiations to commission a variety of treatments both in the cancer drugs fund (CDF) and in routine commissioning. This includes treatments for both rare diseases and more common conditions.

Fifty per cent of total expenditure or £9.6 billion was spent on medications prescribed in primary care and dispensed in the community.

Commenting on these latest figures, Tase Oputu, Chair of RPS England Pharmacy Board said: “Medicines are a fundamental part of our health service, saving and enhancing the lives of millions of people every year.

“These figures highlight more than ever the vital role of pharmacists in medicines optimisation, reducing overprescribing and cutting medicines waste.

“At the same time, pharmacy teams must also be enabled to continue supporting the best use of medicines for patients and not feel pressured into focusing solely on cutting costs.

“The Government and NHS must ensure that local pharmacy leaders have the time and support to develop pharmacy services, working with colleagues across the system. The latest CQC State of Care report showed that this needs additional resources and shouldn’t be an afterthought.

“Investing in pharmacy services can deliver both better outcomes for patients and better value for taxpayers.”

In 2022/23, the total cost of medicines issued in hospitals was £9.45 billion, which accounts for 49.2% of total expenditure.

The total cost to NHS commissioners for medicines prescribed in hospitals and dispensed in the community was £93.6 million.

Drugs worth £32.4 million were prescribed by dentists and dispensed in the community while the total cost for medicines prescribed and dispensed in the Adult Secure Estate was £24.9 million.

The average costs per capita when using Net Ingredient Cost (NIC) for items dispensed in the community for medicines, appliances, and medical devices prescribed in England in 2022/23 across all settings was £349, an increase from £324 in 2021/22.

At £3.26 billion, the British National Formulary (BNF) Chapter 8 – Malignant Disease and Immunosuppression had the highest spend across all settings in 2022/23, accounting for  16.4% of the total spend.

Of this spend, £3.09 billion was for medicines issued and dispensed in hospitals, as shown by the NHSBSA data.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less